has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Sanofi India
to report net profit at Rs 92.5 crore, up 8.4 percent quarter-on-quarter.
Net Sales are expected to increase by 6.1 percent Q-o-Q (up 10.1 percent Y-o-Y) to Rs 645 crore, according to Centrum.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 9.1 percent Q-o-Q (up 12.1 percent Y-o-Y) to Rs 159 crore.
Centrum's report on Sanofi India
For Q3CY16, we expect Sanofi India (SIL) to report sales growth of 10% YoY and 6% QoQ to Rs6.45bn due to good growth in its flagship brands, namely, Lantus, Combiflam, Allegra, Clexane, Enterogermina, Amaryl M, Avil and Pentaxim which have reported strong growth.
Among major brands, Lantus, Cardace, Soframycin, Avil, Clexane, Frisium and Amaryl are under price control. SIL’s net profit is likely to grow 28% YoY to Rs925mn from Rs725mn due to good revenue growth and margin improvement. We expect tax rate to decline to 36.0% from 40.7%. SIL is among our top pharma picks.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.